Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 2
2013 3
2014 3
2015 9
2016 11
2017 16
2018 14
2019 22
2020 17
2021 25
2022 16
2023 12
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean maria del re (5 results)?
EGFR signaling pathway as therapeutic target in human cancers.
Levantini E, Maroni G, Del Re M, Tenen DG. Levantini E, et al. Among authors: del re m. Semin Cancer Biol. 2022 Oct;85:253-275. doi: 10.1016/j.semcancer.2022.04.002. Epub 2022 Apr 12. Semin Cancer Biol. 2022. PMID: 35427766 Review.
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R. Del Re M, et al. Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9. Eur Urol. 2018. PMID: 28801127 No abstract available.
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D. Cremolini C, et al. Among authors: del re m. JAMA Oncol. 2019 Mar 1;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. JAMA Oncol. 2019. PMID: 30476968 Free PMC article. Clinical Trial.
Understanding EGFR heterogeneity in lung cancer.
Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E, Fumagalli C, Pisapia P, Pepe F, De Luca C, Cucchiara F, Troncone G, Danesi R, Spaggiari L, De Marinis F, Rolfo C. Passaro A, et al. Among authors: del re m. ESMO Open. 2020 Oct;5(5):e000919. doi: 10.1136/esmoopen-2020-000919. ESMO Open. 2020. PMID: 33067323 Free PMC article. Review.
Clinical pharmacology of intravitreal anti-VEGF drugs.
Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Fogli S, et al. Among authors: del re m. Eye (Lond). 2018 Jun;32(6):1010-1020. doi: 10.1038/s41433-018-0021-7. Epub 2018 Feb 5. Eye (Lond). 2018. PMID: 29398697 Free PMC article. Review.
Cross-Linked Hyaluronic Acid as Tear Film Substitute.
Posarelli C, Passani A, Del Re M, Fogli S, Toro MD, Ferreras A, Figus M. Posarelli C, et al. Among authors: del re m. J Ocul Pharmacol Ther. 2019 Sep;35(7):381-387. doi: 10.1089/jop.2018.0151. Epub 2019 Aug 2. J Ocul Pharmacol Ther. 2019. PMID: 31373862 Review.
[Biosimilars in oncology. Focus on SB3 studies.].
Del Re M, Del Mastro L. Del Re M, et al. Recenti Prog Med. 2018 Nov;109(11):531-539. doi: 10.1701/3031.30290. Recenti Prog Med. 2018. PMID: 30565572 Review. Italian.
146 results